Cargando…

Increased Mortality in Young-Onset Parkinson’s Disease

OBJECTIVE: Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Hustad, Eldbjørg, Myklebust, Tor Åge, Gulati, Sasha, Aasly, Jan O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorder Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490197/
https://www.ncbi.nlm.nih.gov/pubmed/34315208
http://dx.doi.org/10.14802/jmd.21029
_version_ 1784578479986049024
author Hustad, Eldbjørg
Myklebust, Tor Åge
Gulati, Sasha
Aasly, Jan O.
author_facet Hustad, Eldbjørg
Myklebust, Tor Åge
Gulati, Sasha
Aasly, Jan O.
author_sort Hustad, Eldbjørg
collection PubMed
description OBJECTIVE: Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease onset (AAO) and cognitive decline defined as Montreal Cognitive Assessment (MoCA) score below 26. METHODS: The cohort was followed longitudinally from 1997. By the end of January 2020, 587 patients had died. Comparisons to the Norwegian population were performed by calculating standardized mortality ratios (SMRs). Survival curves were estimated using the standard Kaplan-Meier estimator, and multivariable Cox proportional hazard models were estimated to investigate associations. RESULTS: SMR was 2.28 [95% confidence interval (CI): 2.13–2.44] for the whole cohort. For participants with AAO 20–39 years, the SMR was 5.55 (95% CI: 3.38–8.61). Median survival was 15 years (95% CI: 14.2–15.5) for the whole cohort. Early-onset PD (EOPD) patients (AAO < 50 years) had the longest median survival time. For all groups, there was a significant shortening in median survival time and an almost 3-fold higher age- and sex-adjusted hazard ratio for death when the MoCA score decreased below 26. CONCLUSION: PD patients with an AAO before 40 years had a more than fivefold higher mortality rate compared to a similar general population. EOPD patients had the longest median survival; however, their life expectancy was reduced to a greater degree than that of late-onset PD patients. Cognitive impairment was strongly associated with mortality in PD.
format Online
Article
Text
id pubmed-8490197
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Movement Disorder Society
record_format MEDLINE/PubMed
spelling pubmed-84901972021-10-13 Increased Mortality in Young-Onset Parkinson’s Disease Hustad, Eldbjørg Myklebust, Tor Åge Gulati, Sasha Aasly, Jan O. J Mov Disord Original Article OBJECTIVE: Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease onset (AAO) and cognitive decline defined as Montreal Cognitive Assessment (MoCA) score below 26. METHODS: The cohort was followed longitudinally from 1997. By the end of January 2020, 587 patients had died. Comparisons to the Norwegian population were performed by calculating standardized mortality ratios (SMRs). Survival curves were estimated using the standard Kaplan-Meier estimator, and multivariable Cox proportional hazard models were estimated to investigate associations. RESULTS: SMR was 2.28 [95% confidence interval (CI): 2.13–2.44] for the whole cohort. For participants with AAO 20–39 years, the SMR was 5.55 (95% CI: 3.38–8.61). Median survival was 15 years (95% CI: 14.2–15.5) for the whole cohort. Early-onset PD (EOPD) patients (AAO < 50 years) had the longest median survival time. For all groups, there was a significant shortening in median survival time and an almost 3-fold higher age- and sex-adjusted hazard ratio for death when the MoCA score decreased below 26. CONCLUSION: PD patients with an AAO before 40 years had a more than fivefold higher mortality rate compared to a similar general population. EOPD patients had the longest median survival; however, their life expectancy was reduced to a greater degree than that of late-onset PD patients. Cognitive impairment was strongly associated with mortality in PD. The Korean Movement Disorder Society 2021-09 2021-07-29 /pmc/articles/PMC8490197/ /pubmed/34315208 http://dx.doi.org/10.14802/jmd.21029 Text en Copyright © 2021 The Korean Movement Disorder Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hustad, Eldbjørg
Myklebust, Tor Åge
Gulati, Sasha
Aasly, Jan O.
Increased Mortality in Young-Onset Parkinson’s Disease
title Increased Mortality in Young-Onset Parkinson’s Disease
title_full Increased Mortality in Young-Onset Parkinson’s Disease
title_fullStr Increased Mortality in Young-Onset Parkinson’s Disease
title_full_unstemmed Increased Mortality in Young-Onset Parkinson’s Disease
title_short Increased Mortality in Young-Onset Parkinson’s Disease
title_sort increased mortality in young-onset parkinson’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490197/
https://www.ncbi.nlm.nih.gov/pubmed/34315208
http://dx.doi.org/10.14802/jmd.21029
work_keys_str_mv AT hustadeldbjørg increasedmortalityinyoungonsetparkinsonsdisease
AT myklebusttorage increasedmortalityinyoungonsetparkinsonsdisease
AT gulatisasha increasedmortalityinyoungonsetparkinsonsdisease
AT aaslyjano increasedmortalityinyoungonsetparkinsonsdisease